Floreo expects an FDA answer on FloreoRx this fall. CEO Vijay Ravindran on the two-product plan, CPT 0770T reimbursement, and a family quality-of-life result.
Key Takeaways
- No FDA-authorized therapy for social communication in autism exists today. Ravindran said that absence is the gap FloreoRx was built to fill. A favorable decision would make Floreo the first company in the category and the one that defines its shape.
- The clock runs out this fall on a De Novo request, a pathway distinct from clearance. Ravindran said the submission went in during March, and Floreo announced it publicly on April 20. A grant would be a marketing authorization creating a new device classification, a separate instrument from both the 510(k) and premarket approval routes.
- The pivotal trial ran across 17 Cortica sites in five states and has closed. The ClinicalTrials.gov record, registered as NCT06453629 under protocol number FLO-CL-2023-001, lists a study start of May 31, 2024, a listed completion date of April 3, 2026, and 117 total participants aged five to 18. Ravindran said the most interesting result was a blinded parent-reported gain in family quality of life, including on spousal relationships.
- Reimbursement gets decided in 2027, a year behind the regulatory answer. Ravindran pointed to CPT 0770T, the Category III add-on code covering the practice expense of virtual reality alongside primary ABA codes such as 97153, and to value-based contracts as the two plausible routes. How it settles, he said, will develop over the course of next year.
Floreo is waiting. Vijay Ravindran, the company’s Founder and Chief Executive, said Floreo submitted its De Novo request to the Food and Drug Administration in March, and the company announced the filing publicly on April 20. An answer is expected sometime this fall, and until it arrives there is little to do but hold position. “We’re having a really constructive dialogue with the FDA on what we hope to see as a positive outcome in their evaluation of our submission,” Ravindran told Acuity in an August 31 interview. What rides on that evaluation reaches past one company’s product line. “Today there are no FDA-approved therapies for improving social skills for kids with autism,” he said, “and so, if approved, we believe Floreo would be the first.”
The vocabulary here is slippery, and Ravindran is careful about it himself. Floreo filed a De Novo classification request, the route the agency reserves for devices with no predicate on the market. The two alternatives work differently. A 510(k) clearance turns on showing substantial equivalence to a device already sold, and premarket approval governs the highest-risk class of devices. A De Novo grant is a marketing authorization that establishes a new device classification for low- to moderate-risk devices, which means the first company through the door also builds the door. For most ABA operators, the closest reference point is a diagnostic tool: EarliPoint Health’s eye-tracking assessment, cleared under 510(k) and expanded in March to cover children through age eight. Acuity covered Floreo’s filing when the company announced it in April.
The regulatory apparatus came late. Ravindran founded Floreo in 2016 and took outside capital in 2017, after a career that ran through Amazon’s early retail years and an executive post at The Washington Post. The idea came from home. His son is on the autism spectrum, and the concept arrived by way of the boy’s first time in a headset. “The idea for using virtual reality as a modality for therapy sprang from his first use of virtual reality and some of the benefits I observed early on with how it seemed to connect with him and inspire pretend play and his imagination,” Ravindran said.
His starting thesis concerned the medium itself. His son had received speech and occupational therapy, and Ravindran was drawn to what immersion could do well before he held a view on which discipline would put it to use. “I saw that immersive virtual reality could be a new medium for teaching practical skills through the combination of that immersion and the fact that it could create a repeatable practice environment,” he said. What became clear over the following years, he said, was that ABA sits at the center of the services most families actually receive, and the company has spent much of the past decade refining Floreo so that it fits inside an ABA session instead of alongside one. By Ravindran’s account, more than 60 autism therapy clinics use the commercial platform today.
FloreoRx vs. the Commercial Floreo Platform: What an ABA Clinic Would Actually Buy
For an operator, the practical question is what exactly they would be buying, and Ravindran’s answer is that they would be buying two things. The product Floreo sells now makes no FDA claims. It is a subscription library of virtual reality lessons for social and life skills, and Ravindran said the company will keep investing in it regardless of how the review lands. FloreoRx is built on the same underlying technology but is a different object: a 12-week course of treatment, with lessons sequenced specifically to produce social communication gains, delivered by a behavioral technician or a Board Certified Behavior Analyst inside the therapy session.
“We envision a world where ABA clinics are utilizing FloreoRx to create social communication gains,” Ravindran said. “They might make decisions on using it more than once with the same child.” A clinic could run one course, stop, and run a second later, with the commercial library available in between as supplement or continuation.
The commercial library also reaches into territory FloreoRx leaves alone. Safety instruction is the clearest case, and it is where the argument for the medium is easiest to make. A child can rehearse crossing a street or approaching water in a setting where getting it wrong costs nothing. “You can practice virtually until there’s confidence that they’re ready to go out to the real world,” Ravindran said. “They don’t face any of the negative consequences of getting it wrong in the virtual environment.”
Whether a skill learned in a headset survives contact with an actual sidewalk is what the field calls generalization, and it is the question that has historically separated interesting virtual reality demonstrations from clinically useful ones. Floreo’s earliest published work took it on directly. A usability and feasibility pilot of the company’s Joint Attention Module, by Vijay Ravindran, Monica Osgood, Vibha Sazawal, Rita Solorzano, and Sinan Turnacioglu, ran in JMIR Pediatrics and Parenting in 2019. Ravindran said research since then, separate from the pivotal trial, has continued to show that the sequence holds.
VR Reimbursement in ABA: CPT 0770T, Value-Based Contracts, and a 2027 Timeline
The treatment dose was modest by design, roughly 18 minutes of virtual reality per week across the 12 weeks, which raises an immediate question for providers about what those minutes do to a schedule and to a claim. Ravindran’s position is that they add to a session and leave its structure intact. “We see both the Floreo skills product today that’s available and FloreoRx to be adjunctive tools utilized by healthcare providers,” he said. “We’re not looking to replace therapists. We’re looking to accelerate outcomes and make each session of therapy more effective.” That distinction matters commercially as well as clinically, because autism technology vendors have been experimenting with pricing models that decouple software from billable hours precisely to avoid the appearance of displacing clinician time.
The billing mechanics point the same way. He named CPT 0770T, the Category III add-on code the American Medical Association put into effect in 2023 for virtual reality used during therapy, as one plausible route. The code covers the practice expense of the technology, meaning equipment and technician time but stopping short of any additional clinician time, and it is reported alongside a primary code such as 97153. The second route he described is value-based contracting, in which a provider paid on outcomes has reason to want tools that accelerate them with or without a separate line item. Behavioral health already offers live examples, given how far the shift toward measuring family stress and quality of life has come over the past several years.
Both routes remain unsettled, and Ravindran said as much. “Ultimately, how this plays out is probably something that’s going to develop over the course of 2027,” he said. The caution is warranted, because authorization and payment are separate problems, and the digital therapeutics companies that won FDA clearance years ago and went bankrupt anyway are the standing evidence for the gap between them. What has changed recently is that Medicare has begun paying for the category at all, which gives commercial payers a reference point they lacked until now.
Asked how technology and regulation are likely to intersect as more tools reach ABA, Ravindran was measured. “I think it’s fluid, and ultimately, decisions are going to be made based on what’s in the best interest of the child,” he said, adding that those decisions also have to be cognizant of the economics and the regulatory environment so that abuse is prevented. What he wants, he added, is for that evolution to account for technology that can improve outcomes, with the welfare of the child central to whatever policies result. The backdrop is a code set written before any of this existed. 97153 and 97155 underpin most billable technician and analyst hours in ABA, and both predate the headset by decades. Payers will eventually have to decide what, in that environment, they are paying for.
Inside the FloreoRx Pivotal Trial: 17 Cortica Sites and a Family Quality-of-Life Result
The trial supporting the submission is registered with ClinicalTrials.gov as NCT06453629, under the acronym SoCaVR and the protocol number FLO-CL-2023-001, with Floreo as sponsor and responsible party. The record lists the study as completed, with a start date of May 31, 2024, and a listed completion date of April 3, 2026, which is also the date of Floreo’s most recent update to the record. Ravindran described the study as roughly a two-year effort that concluded at the end of last year, a characterization consistent with the registry’s start-to-completion span, while Floreo’s 15-month figure refers to the narrower window of blinded therapy delivery and crossover. It was a three-arm design: Floreo VR, an active VR control, and a crossover arm in which control participants later received Floreo. Participants used the product twice a week for 12 weeks, and children, their caregivers, and the clinician outcomes assessors were all blinded to assignment.
The registry lists 17 Cortica locations, eight of them in California, with the remainder in Connecticut, Illinois, Massachusetts, and Texas. Floreo’s April announcement described 18 clinical sites and said Cortica enrolled 125 patients; the registry record lists 117 total participants. Eligible children were five to 18 years old with a clinician-verified DSM-5 autism diagnosis, and, notably for anyone reading the results as a guide to their own caseload, they had to already be receiving therapy at least twice a week in a clinic setting. They also had to pass a virtual reality orientation screening. Children with uncontrolled neurological conditions such as epilepsy, with balance disorders, with blindness or deafness, or with eye movement impairment such as strabismus fell outside the protocol.
The result Ravindran volunteered as the most interesting was not about the children. Floreo measured the presentation of autism two ways, through a clinician-observed instrument and a parent-reported one, and also administered the Child and Family Quality of Life questionnaire, second edition, known as the CFQL-2. It is a 26-item caregiver-report instrument covering seven domains of psychosocial quality of life, one of which is partner relationship, validated by Thomas W. Frazier, Allison C. Hyland, Leslie A. Markowitz, Leslie L. Speer, and Elizabeth A. Diekroger in Research in Autism Spectrum Disorders in 2020. Parents were blinded to which arm their child had been assigned, and as the child measures improved, the parents’ own reported quality of life moved with them. “They literally showed a statistically significant presentation of improved spousal relationships,” Ravindran said, “based on being in the treatment arm versus the control arm of the study.”
The registry record carries no posted results, and the trial data has yet to appear in a peer-reviewed journal, so the finding rests for now on the company’s account. Should it survive publication, it lands in a field already arguing about precisely this question. Behavior analysts have spent several years debating whether mastery tables are an adequate account of whether a child and a family are better off, and the discipline’s outcome-measurement problem is unresolved enough that payers moving toward value-based arrangements have started asking for something broader. A blinded parent-reported measure moving in step with a clinician-rated one is the kind of evidence that argument has generally lacked.
“Every progress point we’re able to make with kids with autism has second and third order effects on the overall family’s quality of life and the community’s quality of life,” Ravindran said. He returned to the theme when asked what the work looks like from a parent’s side, which is the vantage he started from. “Parents are constantly seeking to help their child make that next rung of progress on their ladder, and when you have a neurodiverse child, each of those rungs are harder to achieve than if they’re just naturally climbing up the ladder on their own,” he said. “So when you see something work, it’s so exciting and it’s uplifting, and it gives you hope.”
A grant this fall clears the regulatory hurdle and leaves the commercial one standing. Coverage decisions follow separately and on their own schedule, which is why Ravindran’s working timeline for reimbursement is next year rather than this one. The capital markets are watching on a similar lag. Floreo’s last priced round was the $10 million Series A it closed in October 2022. Cleveland Clinic added $1 million in April, and Ravindran has said the company plans a Series B during the review period, at a moment when pediatric therapy dealmaking has held steady rather than accelerated. Ravindran was also explicit that he hopes others follow Floreo through: more authorized options, whether devices or drugs, would mean more choice for families and more tools for therapists. Ten years after a boy put on a headset in his father’s house, the question of whether any of it becomes a prescription gets answered in the next few months.
